Merck, Schering-Plough, and now J&J/Centocor

Monday, March 9, 2009

The Merck/Schering-Plough merger/reverse acquisition may hit some problems according to some because of J&J/Centocor and the co-marketing of Remicade (infliximab). Golimumab is a similar biologic agent that is currently in development. It is supposed to be co-marketed with Schering-Plough, but I guess we're not sure what's going to happen if Merck and Schering-Plough join forces. All these pharma merges/acquisitions are starting to get pretty crazy. Some are forecasting that thousands of jobs may get cut, but no one seems to be sure where those cuts may occur. I guess we'll just have to wait and see what happens here. These are some incredibly dramatic times in the pharma industry.
Posted by Joseph Kim at 4:33 PM
Labels: , , , , ,

Comments

No response to “Merck, Schering-Plough, and now J&J/Centocor”
Post a Comment | Post Comments (Atom)

Post a Comment

Find Jobs:

About Dr. Joseph Kim

My Photo
Dr. Joseph Kim is the founder of NonClinicalJobs.com, an independent website owned and operated by Dr. Kim. He is also the President of MCM Education, a professional medical education and publishing company that develops continuing medical education (CME) activities in joint sponsorship with medical universities, hospitals, and medical associations. Dr. Kim is a digital entrepreneur and technologist who has a passion for health information technology, mobile health, and social media. He frequently speaks at conferences about non-clinical careers for physicians, continuing medical education, mobile health technology, and social media in medicine. Dr. Kim holds a bachelor of science in engineering from the Massachusetts Institute of Technology, a doctorate of medicine from the University of Arkansas College of Medicine, and a master of public health from the University of Massachusetts Amherst School of Public Health.
View my complete profile
Blog Widget by LinkWithin